| Date | Title | Description |
| 19.08.2020 | Kronos Bio Appoints Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development | - |
| 16.07.2020 | Kronos Bio and Gilead Sciences Enter Into Asset Purchase Agreement for Gilead’s SYK Inhibitor Portfolio | - |
| 19.12.2019 | Harvard taps Tishman Speyer to manage first phase of its new 36-acre research campus — and biotechs can’t wait | - |
| 19.12.2019 | UroGen Pharma Announces FDA Filing Acceptance and Priority Review of U.S. New Drug Application (NDA) for UGN-101 | - |
| 20.11.2019 | Kronos Bio Appoints Biopharma Industry Veteran Jorge F. DiMartino, M.D., Ph.D., as Chief Medical Officer | - |
| 11.11.2019 | UroGen Pharma Announces Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract Cancers | - |
| 06.11.2019 | Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T™ Pipeline at 61st American Society of Hematology Annual Meeting | - |
| 05.11.2019 | Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications | - |
| 24.10.2019 | Kronos Bio Strengthens Senior Management Team with New Leadership Appointments | - |
| 24.09.2019 | UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer | - |
| 24.09.2019 | UroGen Investor Day Details Positive Clinical Updates, UGN-101 Launch Preparedness, and Pipeline Advances | - |
| 19.09.2019 | Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies | - |
| 07.08.2019 | Kronos Bio Expands Scientific Advisory Board with Addition of Roger D. Kornberg, Ph.D. | - |
| 05.08.2019 | Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer | - |
| 18.07.2019 | Kronos Bio Completes $105 Million Series A Financing | - |
| 16.07.2019 | Tishman Speyer and Bellco Capital Launch Breakthrough Properties, a First-of-Its-Kind Global Life Sciences Real Estate Platform | - |
| 04.06.2019 | Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy | - |
| 01.05.2019 | Allogene Therapeutics Announces Expansion of Scientific Advisory Board | - |
| 15.04.2019 | Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple Myeloma | - |
| 28.01.2019 | Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T™) Therapy | - |
| 08.01.2019 | UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) | - |
| 03.01.2019 | UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer | - |
| 04.12.2018 | Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting | - |
| 28.11.2018 | Kronos Bio Appoints Philip Gutry as Chief Business Officer to Expand Pipeline Opportunities | - |
| 15.10.2018 | Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | - |
| 10.10.2018 | Allogene Therapeutics Announces Pricing of Initial Public Offering | - |
| 02.10.2018 | FierceBiotech names Kronos Bio as one of its “Fierce 15” Biotech Companies of 2018 | - |
| 27.09.2018 | Allogene Therapeutics Appoints Deborah M. Messemer, Former KPMG Managing Partner, to its Board of Directors | - |
| 14.09.2018 | Allogene Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering | - |
| 06.09.2018 | Allogene Therapeutics Completes a $120 Million Private Financing | - |
| 28.08.2018 | Allogene Therapeutics Appoints David M. Tillett, Ph.D., as Senior Vice President, Head of Quality | - |
| 14.08.2018 | Allogene Therapeutics Appoints Susie Jun, M.D., Ph.D., as Chief Development Officer | - |
| 11.07.2018 | Allogene Therapeutics Announces Scientific Advisory Board | - |
| 18.06.2018 | Allogene Therapeutics Announces Eric T. Schmidt, Ph.D. as Chief Financial Officer | - |
| 05.06.2018 | UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance | - |
| 04.06.2018 | Allogene Therapeutics Appoints Alison Moore, Ph.D. as Chief Technical Officer | - |
| 30.05.2018 | Allogene Therapeutics Announces Board of Directors | - |
| 23.05.2018 | Kronos Bio Appoints Dr. Norbert Bischofberger, Former Head of R&D for Gilead Sciences, as President and Chief Executive Officer and Completes $18 Million Seed Financing | - |
| 21.05.2018 | UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC) | - |
| 16.05.2018 | Sienna Biopharmaceuticals to Present SNA-125 Pre-Clinical Psoriasis Data as Late-Breakter at the International Investigative Dermatology Congress | - |
| 15.05.2018 | Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline | - |
| 03.04.2018 | Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies | - |
| 12.03.2018 | Sienna Biopharmaceuticals announces First Patient Dosed in Proof-Of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis | - |
| 22.02.2018 | Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer | - |
| 22.02.2018 | New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy | - |
| 14.02.2018 | Sienna Biopharmaceuticals announces First Patient Dosed in First-In-Human Trial of Topical SNA-125 | - |
| 14.02.2018 | UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer | - |
| 05.02.2018 | Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy | - |
| 30.01.2018 | Hubble Contacts Launches Subscription Service in the UK | - |
| 23.01.2018 | UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option | - |
| 18.01.2018 | Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma | - |
| 16.01.2018 | Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies | - |
| 08.01.2018 | UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer | - |
| 12.12.2017 | UroGen Pharma Expands Clinical Development Leadership Team | - |
| 11.12.2017 | Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia | - |
| 10.12.2017 | Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma | - |
| 07.12.2017 | Gilead Sciences and Kite to Acquire Cell Design Labs | - |
| 29.11.2017 | Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002 | - |
| 15.11.2017 | Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Investigational Cell Therapy | - |
| 06.11.2017 | UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder | - |
| 02.11.2017 | UroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Directors | - |
| 26.10.2017 | UroGen Pharma Expands Leadership Team, Appoints Industry Veterans Jeffrey Bova as Vice President of Commercial and James Ottinger as Vice President of Regulatory Affairs | - |
| 24.10.2017 | Sienna Biopharmaceuticals announces First Patient Dosed In Phase 2B Trial of Topical SNA-120 | - |
| 18.10.2017 | Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines... | - |
| 06.10.2017 | Capricor Therapeutics Reports Intravenous Administration of CAP-1002 Shown to be Effective in Preclinical Models of Duchenne Muscular Dystrophy | - |
| 04.10.2017 | Capricor Therapeutics Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at World Muscle Society International Congress | - |
| 03.10.2017 | Gilead Sciences Completes Acquisition of Kite Pharma, Inc. | - |
| 06.09.2017 | UroGen Pharma Strengthens Management Team with the Appointment of Paul Chu as Vice President of Business Development | - |
| 29.08.2017 | UroGen Pharma Receives FDA Fast Track Designation for MitoGel™ for the Treatment of Upper Tract Urothelial Carcinoma (UTUC) | - |
| 28.08.2017 | Hubble Contacts Closes Series A-III Financing to Support Global Growth | - |
| 28.08.2017 | Gilead Sciences to Acquire Kite Pharma for $11.9 Billion | - |
| 08.08.2017 | Kite Submits Investigational New Drug (IND) Application for KITE-585, Anti-BCMA CAR-T Therapy Candidate for Multiple Myeloma | - |
| 03.08.2017 | Kite Announces Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma (SCHOLAR-1) Outcomes Published in the Journal BLOOD | - |
| 01.08.2017 | Sienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | - |
| 01.08.2017 | Cell Design Labs Appoints Roger Sidhu, M.D. As Chief Medical Officer | - |
| 31.07.2017 | Kite Files the Industry’s First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel | - |
| 26.07.2017 | Sienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock | - |
| 20.07.2017 | Kite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute | - |
| 19.07.2017 | Investigational New Drug Application for RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder Submitted to FDA by Allergan | - |
| 18.07.2017 | Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystrophy | - |
| 27.06.2017 | Kite Named to the MIT Technology Review’s Annual 50 Smartest Companies List in Recognition for its Leadership in Establishing CAR-T Therapy | - |
| 14.06.2017 | Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of Directors | - |
| 07.06.2017 | Cell Design Labs Announces Issuance of Broad Patent for Chimeric Notch Receptor to Treat Cancer and other Diseases | - |
| 05.06.2017 | Kite Reports 73 Percent of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden Relapsed/Refractory Acute... | - |
| 26.05.2017 | Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel | - |
| 16.05.2017 | UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of Directors | - |
| 10.05.2017 | UroGen Pharma Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option | - |
| 08.05.2017 | Capricor Therapeutics Announces Private Placement of Common Stock | - |
| 25.04.2017 | Capricor Therapeutics Announces Positive Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy | - |
| 24.04.2017 | Sienna Biopharmaceuticals Announces $40 Million Series B Financing | - |
| 24.04.2017 | UroGen Pharma Welcomes New Board Member Kate Falberg | - |
| 06.04.2017 | Kite Wins ‘Clinical Trial Result of the Year’ for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Award... | - |
| 03.04.2017 | UroGen Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial of MitoGel™ for Treatment of Low-Grade Upper Tract Urothelial Carcinoma | - |
| 02.04.2017 | Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Canc... | - |
| 31.03.2017 | Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL) | - |
| 31.03.2017 | New Gene Therapy for Cancer Offers Hope to Those With No Options Left | - |
| 24.03.2017 | Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer | - |
| 20.03.2017 | Hubble Contacts Wants To Do For Contact Lenses What Harry’s Did For Razors | - |
| 15.03.2017 | Cell Design Labs Announces Issuance of a Broad Patent for Programmable CAR-T Cells to Treat Cancer and Other Diseases | - |
| 14.03.2017 | Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditionin... | - |